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a  b  s  t  r  a  c  t
The  Developing  Countries  Vaccine  Manufacturers’  Network  (DCVMN)  held  its  ﬁfteenth  annual  meeting
from  October  27–29,  2014,  New  Delhi,  India.  The  DCVMN,  together  with  the  co-organizing  institution
Panacea  Biotec,  welcomed  over  240 delegates  representing  high-proﬁle  governmental  and  nongovern-
mental  global  health  organizations  from  36  countries.
Over  the  three-day  meeting,  attendees  exchanged  information  about  their efforts  to  achieve  their
shared  goal  of  preventing  death  and  disability  from  known  and  emerging  infectious  diseases.
Special  praise  was  extended  to all  stakeholders  involved  in the success  of  polio  eradication  in  South
East  Asia  and  highlighted  challenges  in  vaccine  supply  for  measles-rubella  immunization  over  the  coming
decades.  Innovative  vaccines  and  vaccine  delivery  technologies  indicated  creative  solutions  for  achieving
global  immunization  goals.
Discussions  were  focused  on three  major  themes  including  regulatory  challenges  for developing  coun-
tries that  may  be  overcome  with  better  communication;  global  collaborations  and  partnerships  for
leveraging  investments  and  enable  uninterrupted  supply  of affordable  and  suitable  vaccines;  and  lead-
ing  innovation  in  vaccines  difﬁcult  to develop,  such  as  dengue,  Chikungunya,  typhoid-conjugated  and
EV71,  and  needle-free  technologies  that  may  speed  up vaccine  delivery.  Moving  further  into  the  Decade
of  Vaccines,  participants  renewed  their  commitment  to shared  responsibility  toward  a world  free  of
vaccine-preventable  diseases.
ublis© 2015  The  Authors.  P
. Introduction
The ﬁfteenth annual Developing Countries Vaccine Manufactur-
rs’ Network (DCVMN) meeting held from October 27–29, 2014
n New Delhi, India, and co-organized by Panacea Biotec, marked
nother year of progress in global vaccination. The DCVMN is a pub-
ic health driven, international alliance of manufacturers, working
o strengthen vaccine supply through information and professional
raining programs, technology improvements, innovative vaccine
esearch and development, encouraging technology transfer ini-
iatives, to improve availability of safe, effective and affordable
accines for all people.
Engagement and participation in this ﬁeld was exempliﬁed
y the high participation of vaccine manufacturers and included
ver 240 delegates from 36 countries, notably 25 percent of
hich were female. Delegates represented major global health
rganizations such as the World Health Organization (WHO),
an American Health Organization (PAHO), United Nations Inter-
ational Children’s Fund (UNICEF), Gavi—The Vaccine Alliance,
overnmental agencies such as the National Institutes for Health
NIH), Japan International Cooperation Agency (JICA), National
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Institute for Biological Standards and Control (NIBSC), United
States Pharmacopeia (USP), United States Department of Health
and Human Services (HHS), and non-governmental organizations
including PATH, Clinton Health Access Initiative (CHAI), Médecins
sans Frontières (MSF), Aeras Foundation, Hilleman Laboratories,
and the Bill & Melinda Gates Foundation, and more than 50
life sciences corporations, including 33 vaccine manufacturers
from developing countries, all working to support the mission of
increasing the quality and availability of affordable vaccines for all
people.
The meeting was jointly opened by M.  Suhardono, President of
DCVMN and Dr. R. Jain, Joint Managing Director of Panacea Biotec;
M.  Suhardono expressed his praise to all vaccination partners for
achieving Polio-free status in the South East Asia region through
targeted and consistent supply of polio vaccines. Dr. R. Jain congrat-
ulated and thanked Panacea employees for over a decade of work to
produce and supply more than 10 billion doses of vaccines to devel-
oping countries. Dr. G.N. Singh, Drugs Controller General of India,
subsequently extended a warm welcome to the global stakeholders
in attendance. Dr. G.N. Singh especially commended the contribu-
tions of developing country vaccine manufacturers to maintaining
healthy populations through the global supply of vaccines. The
leaders noted the growing number of corporate members that
have successfully achieved WHO  pre-qualiﬁcation of vaccines and
thanked all involved stakeholders for their dedication to a healthier
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uture (cf. http://www.who.int/immunization standards/vaccine
uality/PQ vaccine list en/en/).
. Public health priorities for developing countries
The initial session focused on the role of vaccines in addressing
riorities in public health within developing countries, speciﬁ-
ally facilitating access to high-quality and affordable vaccines.
resentations were led by Dr. Bahl (WHO), S. Guichard (WHO), N.
ellepiane (WHO), L. Slamet (Indonesia), and S. Inglis (NIBSC).
The over twenty year history of polio eradication in India was
ummarized by Dr. Bahl from WHO  South East Asia Regional Ofﬁce
SEARO), highlighting the importance of vaccines to the health of
he public. Dr. Bahl attributed the dramatic decline and ultimate
radication of polio to national vaccination campaigns involving
ommunity engagement, diligent work by millions of health work-
rs, an extensive surveillance system to detect incident cases of
olio virus, and strong governmental support. Efforts began in 1978
nd continued until India was ﬁnally removed from the list of polio
ndemic countries on March 27th, 2014, deﬁning the entire WHO
outh East Asia Region as polio-free. India continues to maintain
ational educational campaigns, routine immunization, and strong
urveillance and travel regulations to mitigate the risk of importa-
ion of polio virus.
Highlighting another success story of vaccination on reducing
isease burden in developing countries, S. Guichard from WHO
EARO discussed the Global Measles Elimination Programme ini-
iated in 2000. Countries participating in this programme aim to
chieve over 90 percent vaccination coverage at the national level
nd 80 percent coverage at the district level by 2015. This coverage
evel is sought to reduce incidence of measles to less than 5 cases per
illion total population and mortality from measles by 95 percent.
n South East Asia region, countries have included with measles
limination, the prevention of Rubella and congenital rubella syn-
rome using measles and rubella (MR) combined vaccine. Supply of
R vaccine currently does not meet the amount required to imple-
ent measles elimination and preventing rubella and congenital
yndrome, particularly in the South East Asia Region. Vaccine
anufacturers are addressing the challenges posed by this public
ealth priority, by developing new collaborations and build new
acilities to increase MR  vaccine supply and to achieve WHO  pre-
ualiﬁcation of available products, as soon as possible.
N. Dellepiane, representing WHO’s Regulatory Systems
trengthening team, discussed the regulatory requirements
o supply vaccines to international markets. Dellepiane elabo-
ated on the ﬁve major challenges faced by manufacturers to
egister vaccines in producing and receiving countries. These
hallenges consist of: (1) limited expertise to review technical
roduct information in vaccine regulatory dossiers, (2) lack of
ppropriate expertise and certiﬁed personnel to perform good
anufacturing practice (GMP) inspections in many countries,
3) additional clinical trials requested despite the availability
f sufﬁcient data from trials conducted in other regions, epi-
emiological settings, and socio-economic conditions, (4) limited
ompliance with good clinical practice standards for some clinical
rials, and (5) lengthy registration/review processes which delays
n registration even in emergency situations. WHO  supports
overnments and manufacturers to facilitate effective regulatory
rocess by: (1) developing brieﬁng workshops and guidance
ocuments regarding the pre-qualiﬁcation process for vaccines,
2) holding pre-submission meetings with manufacturers to
iscuss product-speciﬁc dossiers, (3) supporting countries for
apid review and registration of priority vaccines such as biva-
ent oral polio vaccine (bOPV) and inactivated polio vaccine
IPV), and (4) supporting global collaborative networks, such33 (2015) 2197–2202
as DCVMN and the Developing Countries Vaccine Regulators
Network.
S. Inglis, Director of NIBSC, provided his insights into the
importance of pre-licensure dialogue between regulators and the
vaccine industry regarding regulatory processes. Inglis shared the
perspective that, “Good regulators make good manufacturers, and
good manufacturers make good regulators”, since early regulatory
advice can be built into product design phases, saving time and
resources for both manufacturers and regulators.
Highlighting the importance of vaccine safety, L. Slamet
discussed post-licensure communication among regulators and
industry to ensure that vaccination beneﬁts outweigh foreseeable
risks for users. Slamet encouraged manufacturers from developing
countries to clearly communicate beneﬁts and risks with gov-
ernments, NGOs, regulators, health professionals, and patients to
increase and maintain conﬁdence in vaccines.
3. Global collaborations and partnerships for vaccine
supply
The DCVMN annual meeting continued with discussion regard-
ing collaborations and partnerships for vaccine supply. Presenters
for this topic were O. Levine (BMGF), D. Mulenga (UNICEF), M.
Pereira (PAHO), M.  Malhame (Gavi), J. Schafer (National Biomed-
ical Advanced Research and Development Authority (BARDA)), C.
Egerton-Warburton (Global Health Investment Fund (GHIF)), Y.
Ikeda (JICA), D. Saha (USP), R. Salerno (Sandia National Laborato-
ries), and K. Sampson (Asia Paciﬁc Alliance for Control of Inﬂuenza
(APACI)).
The topic was opened by O. Levine, Director of Vaccine Delivery
at BMGF. BMGF aims to support prevention of 11 million deaths, 3.8
million disabilities, and 230 million illnesses by 2020, through high,
equitable, sustainable vaccine coverage. Levine discussed three
main goals proposed by BMGF for collaborations and partnerships
across the vaccine market, including: (1) ensuring uninterrupted
supply of affordable and suitable vaccines for Gavi, (2) improving
the market dynamics information and expertise to solve vaccine
access challenges, (3) strengthening global health and manufac-
turers’ partnerships to enable better alignment of goals, alignment
with global strategy, and coordination of internal investments.
D. Mulenga, Deputy Director of the Supply Division at UNICEF,
updated attendees about the vaccine procurement required to
achieve a sustained and uninterrupted supply of affordable, high-
quality vaccines. Echoing the prior presenters, Mulenga pointed
to rapidly increasing demand for vaccines such as pentavalent,
Bacillus Calmette–Guérin (BCG), pneumococcal, rotavirus, and
measles-rubella (MR), and the insufﬁcient supply. Further, Mulenga
pointed to the challenge to achieve the Decade of Vaccines’ goal of
90% vaccination coverage nationally, since coverage is stagnating
in some countries [1]. This challenge is further enhanced by the fact
that less than 30% of the poorest countries meet the WHO  standards
for an adequate vaccine supply chain [2]. Opportunities exist for
new manufacturers to leverage supply of vaccines, already licensed
and available in domestic markets, to other developing countries
through UNICEF pooled procurement; yet these vaccines must be
pre-qualiﬁed by WHO, which is a condition for international pro-
curement.
M. Pereira from PAHO discussed the global collaboration
through the PAHO Revolving Fund for vaccine procurement in the
Americas. Launched in 1979 as a technical cooperation programme
and mechanism to procure essential vaccines, syringes, and other
related supplies, the Revolving Fund relies on strong principles of
regional solidarity and ﬁnancial self-sustainability. The achieve-
ment of regional polio eradication, and measles and rubella elimi-
nation reﬂect its success. Further, between 80 and 90% of countries






























































Fig. 1. Biorisk assessment phases for continual improvement. Biorisk assessment
should rely on constant monitoring and evaluation for continual improvement.
Organizations can use a structured risk assessment process tool that has been subject
to  peer review, address the pertinent questions, is repeatable and allows decision
makers to make informed decisions about project planning, mitigation measures,Conference report / Va
n the Americas have already introduced new pneumococcal,
uman papilloma virus (HPV), and rotavirus vaccines. Challenges
emain to be resolved, such as disruption of vaccines’ supply, lim-
ted competition for vaccines produced by few manufacturers, and
emand increasing faster than supply. PAHO’s efforts to improve
eliability of the demand forecast, increased planning capabilities,
nd awarding longer-term contracts will improve supply security.
Discussing the Gavi, the Vaccine Alliance strategy, M.  Mal-
ame provided an overview of Gavi’s supply and procurement
nitiatives. Malhame’s presentation highlighted the many new
accine introductions in 2014 and the routine availability of
entavalent vaccine in all 73 Gavi countries. Speciﬁc vaccine
ctivities were discussed including new yellow fever cam-
aigns, the achievement of a stockpile of cholera vaccine, the
urrent window of opportunity for malaria vaccines, the assess-
ent of rabies prophylaxis, and the impact of the maternal
nﬂuenza vaccination. Malhame also focused on the remaining
ncertainties concerning pricing of vaccines post-Gavi ﬁnancing.
emporarily dispelling this concern are the commitments of two
anufacturers to a ﬁve year price-freeze for pentavalent vac-
ines for countries graduating from Gavi’s ﬁnancial support (cf.
ttp://www.gavi.org/pledging2015/private-sector/).
J. Schafer, from BARDA discussed approaches to ensuring vac-
ine preparedness for global pandemic inﬂuenza. Preparedness
ntails generating the capacity to supply vaccines to a majority of
he population within six months of pandemic declaration, estab-
ishing and maintaining stockpiles of vaccines to cover about 10
ercent of the population, and enhancing sustainable inﬂuenza
accine production capacity in developing countries. Preparedness
hould be created through technical support of developing country
accine manufacturers, facilitating license agreements for technol-
gy transfer, and innovation such as use of adjuvant formulation
o increase vaccine doses delivery. Schafer suggested using a tool
eveloped by the United States Centers for Disease Control and Pre-
ention (CDC) to assess risk factors of the virus, attributes of the
opulation, and environmental and epidemiological components
f the pandemic [3].
The Global Health Investment Fund (GHIF) was  introduced by
. Egerton-Warburton who described the fund as providing a new
tream of capital to projects or product development efforts aimed
t addressing infectious diseases. The main objectives of GHIF
re to enable new products, encourage affordable prices, promote
reater product supply, develop new markets, and encourage col-
ection of data. To date, 70 investment opportunities have been
eviewed by the Fund’s investment committee, such as tuber-
ulosis (TB) diagnostic products and oral cholera vaccines from
uBiologics. GHIF is actively seeking additional investment oppor-
unities.
Y. Ikeda discussed the collaborations and partnerships in which
ICA is involved regarding vaccine manufacturing and immuniza-
ion. Control of infectious diseases is of high priority for JICA both
omestically and internationally. The transfer of an oral polio vac-
ine (OPV) technology from Biken to Biofarma was  instrumental in
atisfying worldwide demand and gave ground to global polio erad-
cation efforts. In partnership with BMGF, JICA also supports vaccine
rocurement through a “loan conversion mechanism” for polio
radication in Pakistan and Nigeria. JICA is currently supporting the
ransfer of a MR  vaccine manufacturing technology from Japan to
olyvac in Vietnam, following the precedent set by multiple previ-
us successful projects. JICA supports UNICEF supply of vaccine cold
hain equipment to India, Afghanistan, Angola, Liberia, Zambia, and
imbabwe.D. Saha introduced the work of the USP which is recognized
s an ofﬁcial compendium determining and compiling the qual-
ty standards for drugs and biological products enforced by the
nited States regulatory authorities. In collaboration with globaland communication. Available at www.biosecurity.sandia.gov/BioRAM. Figure is a
courtesy of R. Salerno.
institutions such as NIBSC and WHO, USP develops product mono-
graphs, reference materials standards, and training programs in
microbiology, biotechnology, and pharmacopeia analysis. D. Saha
concluded by inviting vaccine experts to volunteer as candidates
to the USP Council of Experts and the Expert Committees for the
2015–2020 Convention cycle.
R. Salerno from Sandia National Laboratories highlighted the
recent Ebola outbreak in West African countries as exemplary of
the risks to the vaccine manufacturing industry that are posed by
emerging and reemerging infectious diseases. It is the ultimate
aim of vaccine manufacturers to protect vaccine users from unsafe
products, protect employees and the environment from harmful
agents, and prevent dangerous materials and proprietary informa-
tion from malicious uses. Sandia has developed a tool to assist
decision makers in deﬁning risk criteria and making informed
decisions in planning, mitigation, and communication of biorisks
(Fig. 1). Sandia is partnering with DCVMN to offer risk-assessment
training to vaccine manufacturers.
This session concluded with a presentation by K. Sampson who
introduced APACI. APACI serves as a trusted and independent
source of information for decision makers and the public to foster
best practices in prevention and treatment of inﬂuenza. Initiated in
2002 as a working committee modeled on the Inﬂuenza Specialist
Group in Australia, APACI educates key opinion leaders and works
with governments and institutions to enhance pandemic planning.
Through educational awareness and public information the num-
ber of inﬂuenza vaccine doses deployed in Australia, have increased
from 500,000 in 1991 to over 7 million in 2014.
Overall, these presentations encouraged successful global col-
laborations and partnerships to continue and urged new ones to be
initiated all under the goal of increasing vaccine supply.
4. Innovation in vaccines’ and delivery technologies
New frontiers in vaccination were discussed within presenta-
tions on vaccine innovations and delivery technologies offered by
G. Madhavan (Institute of Medicine, National Academy of Sciences),
J. Kalil (Butantan), R.K. Suri (Panacea Biotec), R. Mehta (Cadila
Biotech), A. Nanni (Aeras), K. Ella (Bharat Biotech International), Dr.
T.S. Rao (India Department of Biotechnology), W.Meng (Sinovac),
X. Liao (Innovax), R. Steinglass (JSI), D. Zehrung (PATH), S. Jadhav
(Serum Institute of India), D. Kristensen (PATH), C. Collins (CHAI),




























































intranasal vaccine delivery technologies were discussed, includ-
ing an inhalable dry powder vaccine for measles applied with a200 Conference report / Va
Opening the discussion, G. Madhavan from Institute of Medicine
poke about the importance of strategic planning for prioritizing
ew vaccine development and policy. Historically, vaccine devel-
pment projects were prioritized by infant mortality equivalents
life years saved) or cost-effectiveness. Madhavan demonstrated
he use of a decision-support software tool called Strategic Multi-
ttribute-Ranking-Tool for Vaccines—or “SMART Vaccines” to
ssist in vaccine priority setting efforts. Developed over multiple
hases, this software provides transparency in vaccine compari-
on, thus facilitating discussions among various stakeholders in the
accine enterprise [4–7].
J. Kalil from Butantan focused the dialogue on vaccines that
emain difﬁcult to develop, yet necessary to ensure health world-
ide. The discussion initially focused on the difﬁcult process of
eveloping a vaccine against Streptococcus pyrogenes to prevent
heumatic heart diseases. Another example provided was a T-cell
ulti-epitope based HIV vaccine, which is already being tested on
 primate animal model [8]. Finally, Kalil discussed the live atten-
ated tetravalent dengue vaccine candidate under evaluation and
he trial design for related phase II and III studies.
Another innovative vaccine, the Sabin-IPV project, was  pre-
ented by R.K. Suri from Panacea Biotec. Under a charge by the
orld Health Assembly to develop “safer processes for production
f IPV and affordable strategies for its use in developing countries”
9], the WHO, BMGF, and a Netherlands government laboratory
ave collaborated to ensure availability of Sabin-IPV through public
ector channels in developing countries. Following promising per-
ormance in preclinical and clinical studies [10], Panacea Biotec was
elected as one of the manufacturers to receive technology transfer
f the vaccine manufacturing process.
R. Mehta from Cadila Biotech presented the virus like particles
VLPs)-based recombinant technology for vaccine development.
he self-assembling feature of recombinant VLPs offers efﬁ-
ient expression of 3-dimensional structures, good stability, high
mmunogenicity, and non-infectiousness safety. This innovative
echnology platform can be used to speed up the delivery of
andemic inﬂuenza vaccine doses released 10 to 12 weeks after
loning, while traditional production methods require 20 weeks
fter virus inoculation. The VLPs technology has been transferred to
n Indian facility and has been validated for production of inﬂuenza
accines.
From Aeras Foundation, A. Nanni outlined TB as the top infec-
ious disease killer from the past century. While TB treatments cost
he global economy an estimated 1 billion dollars daily, funding for
ew vaccine development is insufﬁcient to produce viable solu-
ions. Additionally, antibiotic resistance confounds global efforts
o control the epidemic allowing some evolving strains to become
irtually untreatable. Engagement of large vaccine manufacturing
nstitutions within developing countries is vital to support effec-
ive TB vaccine development, future vaccine supply, and ultimately
eduction of the disease burden.
A presentation by K. Ella from Bharat Biotech International pro-
ided an overview of domestic and international partnerships to
evelop innovative vaccines. Ella discussed vaccines for neglected
iseases such as Chikungunya, and discussed its launch of the
ovel typhoid conjugate vaccine. This institution also supported
he development of the ﬁrst indigenous rotavirus vaccine called
OTAVAC®, recently approved for pilot introduction in India.
T.S. Rao, from India Department of Biotechnology, asserted that
accines are the fastest growing area within the pharmaceutical
nd biological sectors in India. Rao announced a new Vaccine Grand
hallenge Program with the objective of accelerating development
f promising candidate vaccines through pre-clinical and clinical
evelopment and commercialization [11].
The Enterovirus 71 vaccine was discussed by W.  Meng from
inovac. This vaccine addresses hand, foot, and mouth disease33 (2015) 2197–2202
which was ﬁrst reported in New Zealand in 1957 and has continued
to present an increasing number of cases globally [12]. Devel-
opment of a vaccine against this disease is necessary to prevent
related morbidity and mortality. A Vero cell-based, inactivated vac-
cine candidate has been tested in a clinical trial with over 11,000
subjects, demonstrating safety, immunogenicity, and high efﬁcacy
[13]. The vaccine is currently being optimized for large scale man-
ufacturing and is expected to be available soon.
X. Liao from Innovax talked about innovations in the HPV vac-
cine, a vaccine that is increasingly important as incidence of cervical
cancer tends to rise, especially in developing countries [14]. While
two HPV vaccines have been available since 2006, only 30 percent
of countries worldwide have introduced them in national immu-
nization programs. The high cost of these HPV vaccines remains a
barrier for poor countries. Furthermore, immunogenicity requires
three doses of the currently available HPV vaccines, while WHO
recommends a two dose schedule, provided vaccination is initiated
prior to 15 years of age4. Innovax aims to launch a new vaccine by
2018 that is currently in phase III clinical trials, with the aim to
accelerate access to affordable HPV vaccines and reduce incidence
of cervical cancer globally.
New approaches to vaccine delivery were shared by R. Stein-
glass, from John Snow Inc. Steinglass discussed that immunization
managers have become more informed customers with prefer-
ences for vaccine formulations, presentations, and packaging that
ﬁt well with their programs. Additionally, they are concerned
about heat stability, storage temperatures, storage volumes, waste
volume, ease of preparation and administration, and volume of
dose administered. Steinglass encouraged vaccine manufacturers
to research their markets to learn the product preferences directly
from prospective clients and discussed the importance of incor-
porating these preferences earlier in the manufacturing process.
Steinglass suggested consulting WHO’s “Assessing the Program-
matic Suitability of Vaccine Candidates for Pre-Qualiﬁcation” which
lists preferred characteristics of vaccines [15].
D. Zehrung, from PATH provided an overview of new vac-
cine delivery technologies, including delivery devices and novel
primary, packaging, and formulations for traditional and novel
vaccines. New delivery technologies included needle free devices
to improve efﬁcacy, safety, cost-effectiveness and public health
beneﬁts of vaccines. Zehrung discussed how new immunisation
technologies may bring the potential beneﬁts of increased access
and coverage, and lower cold chain capacity requirements. Ideally,
vaccine manufacturers may  consider early integration of innova-
tive technologies by aligning the vaccine development process with
the preferred product proﬁle recommendations of the Vaccine Pre-
sentation and Packaging Advisory Group (VPPAG) and with the
requirements of WHO  guidelines on programmatic suitability of
vaccine candidates for pre-qualiﬁcation [15].
S. Jadhav provided an overview of nasal and aerosol vaccines,
currently in development at the Serum Institute of India. Jadhav
discussed lessons learned from OPV campaigns which empha-
size the importance of ease-of-use, acceptability, affordability, and
safety. The characteristics of being painless, easy to administer, and
safer than needle administration make intranasal vaccine deliv-
ery technologies potentially more acceptable, while the fact that
these vaccines mimic  natural infection and induce the appropriate
immune response make them potentially more effective. Multiple4 In April 2014, The Strategic Advisory Group of Experts (SAGE) on Immunization
recommended a two  dose regimen of the vaccine provided vaccination is initiated
prior to age 15 based on review of evidence.
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Fig. 2. Estimated lives saved in Middle Income Countries (MICs) by vaccination improvements. The bar-chart shows graphically the estimated number of lives saved (in thousands)
by  reduction of Vaccine Preventable Diseases (VPD) in Middle Income Countries (MICs) in the next decade if the vaccination coverage improves to 90% by 2015. The major
vaccination components driving improvements include: major gains in lives saved by increase of traditional vaccine coverage to 90% (dark grey part of the bar) and





































rntroduction of PCV or Rotavirus vaccines to 90% in middle income countries (red pa
stimates (2013) for DTP3, Hib, HepB, measles, PCV, and Rota. Traditional vaccines i
baseline)-2025, coverage increasing linearly to 90%. If coverage is above 90% in 201
uffHaler device [16] and a lyophilized nasal spray for live attenu-
ted inﬂuenza vaccine.
D. Kristensen from PATH presented three trends in vac-
ine packaging and labeling: (1) improvement of tracking and
racing capability through added barcoding on secondary and ter-
iary packaging, (2) improvement of storage capability through
inimization of container dimensions for primary to tertiary pack-
ging, and (3) efﬁciencies for delivering vaccines in a “controlled
emperature chain” by labeling the vaccines for limited storage at
igher-temperature. The VPPAG has been advancing public and pri-
ate sector dialogue and work in all three areas while updating
he preferred product proﬁle for vaccines to reﬂect the consensus
ecommendations reached by the group.
Improving the vaccine supply chain in developing countries
as discussed by C. Collins from CHAI who suggested increasing
se of freeze-protected cold chain equipment. A CHAI review of
xisting data found that freeze exposure occurred in 18 to 67 per-
ent of vaccine shipments throughout various stages of storage.
uch exposure may  reduce vaccine potency, ultimately providing
accines with potentially less-effective vaccines. Total demand for
accine refrigerators is expected to reach 110,000 units by 2018
n the 53 Gavi-eligible countries, making it increasingly vital that
reeze-protected equipment is used to prevent damage to vaccines.
The closing presentation focused on sustainable vaccine sup-
ly in middle income countries (MICs), presented by T. Cernuschi
rom WHO’s Expanded Program on Immunization. MICs continue
o report high mortality from diseases that are preventable by
mmunization [17]. The vast majority of the world’s unvaccinated
hildren reside in MICs. While a large share of these MICs is
ell supported by donors, sixty-three countries are not beneﬁt-
ing from a uniﬁed international strategy for immunization. In
hese countries vaccine-preventable disease burden and unvac-
inated children is currently relatively low, but substantial and
nacceptable nonetheless. Many of these countries have strong
ystems and the potential to make rapid gains in vaccination cov-
rage if key barriers are removed. WHO  established a task force
o investigate obstacles to new vaccine adoption and mobilize
esources for improving immunization in neglected MICs. A recenthe bar) by 2025. Lives saved estimation conducted on LiST: WHO/UNICEF coverage
e: DTP3, Hib, HepB, and measles. New vaccines include: PCV and Rota. Range: 2014
t consistent to 2025. Figure is a courtesy of T. Cernuschi.
analysis revealed that signiﬁcant reduction of deaths by vaccine-
preventable diseases can be achieved both through introductions
of new vaccines and through increased coverage of traditional
vaccines to 90 percent by 2025 in middle-income countries as illus-
trated in Fig. 2.
5. Conclusion
Attendees to the 2014 DCVMN annual conference left the meet-
ing reinvigorated to continue their collaborative efforts preventing
the spread of infectious diseases worldwide through improving
vaccination coverage. Four areas of action were jointly identiﬁed
to strengthen and foster sustainable vaccine supply from DCVMs:
(1) review manufacturing facilities design layout and infrastruc-
ture, (2) provide adequate training on evolving good manufacturing
practices, quality management systems, and the WHO  prequal-
iﬁcation process, (3) encourage dialogue to resolve regulatory
challenges, and (4) facilitate access to independent experts able
to resolve vaccine industry issues.
United by a shared responsibility for a global community free
of infectious diseases, DCVMN members and partners foster the
development and supply of safe, effective, and affordable vac-
cines for future generations. Presentations of this conference are
available on the DCVMN website at http://www.dcvmn.org/event/
dcvmn-15th-annual-general-meeting.
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